-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Philochem Licenses Global Rights To Prostate Cancer Radiopharmaceutical OncoACP3 To RayzeBio, A Bristol-Myers Squibb Company, In Deal Worth Up To $1.35B

Benzinga·06/11/2025 06:59:32
Listen to the news

Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales